{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Hayase E"],"funding":["American Society for Transplantation and Cellular Therapy","NIDDK NIH HHS","National Marrow Donor Program","NHLBI NIH HHS","NCI NIH HHS","National Institutes of Health","DKMS Foundation UK","Cancer Prevention and Research Institute of Texas"],"pagination":["1621-1636.e6"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11441101"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["32(9)"],"pubmed_abstract":["Acute lower gastrointestinal GVHD (aLGI-GVHD) is a serious complication of allogeneic hematopoietic stem cell transplantation. Although the intestinal microbiota is associated with the incidence of aLGI-GVHD, how the intestinal microbiota impacts treatment responses in aLGI-GVHD has not been thoroughly studied. In a cohort of patients with aLGI-GVHD (n = 37), we found that non-response to standard therapy with corticosteroids was associated with prior treatment with carbapenem antibiotics and a disrupted fecal microbiome characterized by reduced abundances of Bacteroides ovatus. In a murine GVHD model aggravated by carbapenem antibiotics, introducing B. ovatus reduced GVHD severity and improved survival. These beneficial effects of Bacteroides ovatus were linked to its ability to metaboliz"],"journal":["Cell host & microbe"],"pubmed_title":["Bacteroides ovatus alleviates dysbiotic microbiota-induced graft-versus-host disease."],"pmcid":["PMC11441101"],"funding_grant_id":["P01 HL170046","P30 CA016672","R01 HL158796","P30 CA008748","P30 DK056338","R35 HL155672","K08 HL143189","R01 HL124112"],"pubmed_authors":["Wong MC","McDaniel LK","Pham D","Katsamakis Z","Prasad R","Okhuysen PC","Mukherjee A","Wargo JA","Schmiester M","Chang CC","Fowler SW","Ortega MR","Tan L","Britton RA","Stinson SC","Glover IK","Burgos da Silva M","King KY","Jin Y","Karmouch JL","Jamal MA","Ponce DM","Martens EC","Mohammed A","Halsey TM","Mehta RS","Alousi AM","Reddy P","Ajami NJ","Hayase E","Enkhbayar A","Lorenzi PL","van den Brink MRM","Peterson CB","Rondon G","Ahmed SS","Brown AN","Tsai WB","Molldrem JJ","Shpall EJ","Tran BQ","Fan C","Sanchez CA","Xiao Y","Peled JU","Jenq RR","Chapa VA","Conner ME","Smith N","Shelburne S","Liu C","Flores II","El-Himri RK","Hayase T","Champlin RE"],"additional_accession":[]},"is_claimable":false,"name":"Bacteroides ovatus alleviates dysbiotic microbiota-induced graft-versus-host disease.","description":"Acute lower gastrointestinal GVHD (aLGI-GVHD) is a serious complication of allogeneic hematopoietic stem cell transplantation. Although the intestinal microbiota is associated with the incidence of aLGI-GVHD, how the intestinal microbiota impacts treatment responses in aLGI-GVHD has not been thoroughly studied. In a cohort of patients with aLGI-GVHD (n = 37), we found that non-response to standard therapy with corticosteroids was associated with prior treatment with carbapenem antibiotics and a disrupted fecal microbiome characterized by reduced abundances of Bacteroides ovatus. In a murine GVHD model aggravated by carbapenem antibiotics, introducing B. ovatus reduced GVHD severity and improved survival. These beneficial effects of Bacteroides ovatus were linked to its ability to metaboliz","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Sep","modification":"2026-06-03T05:46:54.592Z","creation":"2026-04-25T03:14:45.514Z"},"accession":"S-EPMC11441101","cross_references":{"pubmed":["39214085"],"doi":["10.1016/j.chom.2024.08.004"]}}